Rossari Biotech Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fnvu8ouwek5d78aphned7djr.pdf

Key Takeaways


Top-Line Performance & Growth Drivers

Edward Menezes: "I think the biosurfactants, the NMMO, the spray-cooled powders, the fibre finishes that we have introduced, as well as the vitamin premix plant which has become operational, all these have started contributing very handsomely to the top line now."

Margin Walk & Cost Headwinds

Ketan Sablok: "In anticipation that the prices would go up further, we did a slightly larger block of purchase, but then the market moved the other way."
Sunil Chari: "We will not stop seeding these initiatives just to show a slightly higher EBITDA margin."

Portfolio Reshaping: B2C Exit & Non-Core Monetization

Sunil Chari: "Once you see the exit of some businesses which we are working very hard, you will definitely see the margin improvement."

Capacity Build-Out & New Initiatives


Saudi Arabia: Long-Gestation Bet


EO Dependency & the FY28 Inflection


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin floor11.6% as the base level; margins not expected to go below thisOngoing from Q1 FY27
Consolidated EBITDA margin target15%+ at consolidated levelAchievable in two years
FY27 top-line growthAround 15%FY27
B2C business exitExit the consumer business; institutional cleaning products business retainedNo date given; "working very hard"
Pharma business ramp-upMost compliances done; ₹30–₹50 crore revenue potentialEnd of Q2 or Q3 FY27
MDEA plant ramp-upRamp-up with higher marginsNext 12 months
Additional EO availabilityMore EO supply coming on streamBefore December (end of calendar year)
KSA project first productionFirst kilo of production post-announcement~1.5 years from announcement date
Scaling targetMore than double Rossari's sizeOver the next four years

Key Metrics

MetricQ1 FY27
Revenue from operations₹697.2 cr, +28% YoY, highest ever quarterly revenue
EBITDA₹80.6 cr, +18.7% YoY, highest ever quarterly EBITDA
EBITDA margin11.6%, vs 12.5% in Q1 FY26
Core B2B EBITDA₹85 cr, +13% YoY, with EBITDA margin of approximately 14%
PAT₹35.1 cr, +4.5% YoY
HPPC segment revenueCrossed ₹550 cr quarterly milestone
HPPC, TSC, AHN segment growth~28% YoY each
Exports~₹160 cr, 23%-24% of total revenue, +20%-21% YoY
Volume growth~10% YoY, rest of growth from higher pricing
Net debt₹248 cr, down from ₹280 cr in March 2026
Interest cost run rate₹9 cr – ₹10 cr per quarter going forward
FY27 revenue growth guidance~15%, management sticking to earlier estimate
Pharma revenue target FY27₹70 cr – ₹75 cr, up from more than ₹50 cr in FY26
One-off phenol hit~₹5 cr impact on the quarter
EO capacity utilizationPractically 100% utilized except for small addition in batch reactors